Scaling approach in steady state [Design Issues]

posted by AB – India, 2013-01-10 09:42 (4917 d 11:19 ago) – Posting: # 9811
Views: 4,227

Dear All,

Can we adopt a ref scaling approach in a steady state design for highly variable drugs?
if yes, in such cases what are the parameters to consider for the scaling for USFDA & EMA submission studies.

Many thanks in advance.

Regards,
AB

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
334 visitors (0 registered, 334 guests [including 19 identified bots]).
Forum time: 22:02 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5